J Clin Neurol.  2016 Jul;12(3):340-344. 10.3988/jcn.2016.12.3.340.

Incidence and Prevalence of Myasthenia Gravis in Korea: A Population-Based Study Using the National Health Insurance Claims Database

• Park SY
• Lee JY
• Lim NG
• Hong YH

• KMID: 2354122
• DOI: http://doi.org/10.3988/jcn.2016.12.3.340

Abstract

BACKGROUND AND PURPOSE
There have been a few national population-based epidemiological studies of myasthenia gravis (MG) with wide variation of incidence and prevalence rates worldwide. Herein we report the first nationwide population-based epidemiological study of MG in Korea.
METHODS
We attempted to estimate the incidence and prevalence rates of MG using the Korean National Health Insurance claims database for 2010 to 2013. Cases with MG were defined as those having claim records with a principal diagnosis of MG and the prescription of acetylcholinesterase inhibitors or immunosuppressive agents including corticosteroids and azathioprine within 2 years after the diagnosis. The year 2010 was set as a washout period, such that patients were defined as incident cases if their first records of MG were observed in 2011.
RESULTS
In 2011 there were 1,236 incident cases, and the standardized incidence rate was 2.44 per 100,000 person-years. The standardized prevalence rates were 9.67 and 10.66 per 100,000 persons in 2010 and 2011, respectively. The incidence and prevalence rates peaked in the elderly population aged 60 to 69 years for both sexes.
CONCLUSIONS
This is one of the largest national population-based epidemiological studies of MG, and it has confirmed the high incidence and prevalence rates of MG in the elderly population of South Korea.

Keyword

myasthenia gravis; epidemiology; incidence; prevalence; Korea

MeSH Terms

Adrenal Cortex Hormones
Aged
Azathioprine
Cholinesterase Inhibitors
Diagnosis
Epidemiologic Studies
Epidemiology
Humans
Immunosuppressive Agents
Incidence*
Korea*
Myasthenia Gravis*
National Health Programs*
Prescriptions
Prevalence*
Adrenal Cortex Hormones
Azathioprine
Cholinesterase Inhibitors
Immunosuppressive Agents

Reference

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8:475–490.

2. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun. 2014; 48-49:143–148.

3. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010; 10:46.

4. McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology. 2010; 34:171–183.

5. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in taiwan. Neuroepidemiology. 2010; 35:66–71.

6. Phillips LH 2nd, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996; 47:1233–1238.

7. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand. 1984; 70:274–284.

8. Ferrari G, Lovaste MG. Epidemiology of myasthenia gravis in the province of Trento (northern Italy). Neuroepidemiology. 1992; 11:135–142.

9. Christensen PB, Jensen TS, Tsiropoulos I, Sørensen T, Kjaer M, Højer-Pedersen E, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology. 1993; 43:1779–1783.

10. Somnier FE, Engel PJ. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology. 2002; 59:92–98.

11. Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. UK Myasthenia Gravis Survey. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003; 74:1105–1108.

12. Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol. 2003; 250:698–701.

13. Aragonès JM, Bolíbar I, Bonfill X, Bufill E, Mummany A, Alonso F, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology. 2003; 60:1024–1026.

14. Casetta I, Fallica E, Govoni V, Azzini C, Tola M, Granieri E. Incidence of myasthenia gravis in the province of Ferrara: a community-based study. Neuroepidemiology. 2004; 23:281–284.

15. Lavrnic D, Basta I, Rakocevic-Stojanovic V, Stevic Z, Peric S, Nikolic A, et al. Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008. Neuroepidemiology. 2013; 40:190–194.

16. Casetta I, Groppo E, De Gennaro R, Cesnik E, Piccolo L, Volpato S, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010; 257:2015–2019.

17. Pallaver F, Riviera AP, Piffer S, Ricciardi R, Roni R, Orrico D, et al. Change in myasthenia gravis epidemiology in Trento, Italy, after twenty years. Neuroepidemiology. 2011; 36:282–287.

18. Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology. 2011; 76:1526–1528.

19. Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005; 65:928–930.

20. Matsui N, Nakane S, Nakagawa Y, Kondo K, Mitsui T, Matsumoto T, et al. Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry. 2009; 80:1168–1171.

21. Yu YL, Hawkins BR, Ip MS, Wong V, Woo E. Myasthenia gravis in Hong Kong Chinese 1 Epidemiology and adult disease. Acta Neurol Scand. 1992; 86:113–119.

22. Zhang X, Yang M, Xu J, Zhang M, Lang B, Wang W, et al. Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry. 2007; 78:386–390.

23. Mao ZF, Mo XA, Qin C, Lai YR, Hackett ML. Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol. 2012; 8:161–169.